Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 21 November, 2024
Author: Getaka|Social: Getaka Financial Services X (Earlier Twitter) Profile Getaka Financial Services LinkedIn Logo

J B Chemicals & Pharmaceuticals Ltd: Intrinsic Value and Fundamental Analysis

Share Price and Basic Stock Data

Last Updated: November 21, 2024, 9:58 pm

Market Cap 26,454 Cr.
Current Price 1,702
High / Low2,030/1,371
Stock P/E43.3
Book Value 207
Dividend Yield0.72 %
ROCE24.6 %
ROE20.0 %
Face Value 1.00
PEG Ratio3.20

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for J B Chemicals & Pharmaceuticals Ltd

Competitors of J B Chemicals & Pharmaceuticals Ltd

Stock NameMarket CapCurrent PriceHigh / LowStock P/EBook ValueDividend YieldROCEROEFace Value
Gujarat Themis Biosyn Ltd 3,465 Cr. 318390/10865.7 20.50.21 %45.0 %33.8 % 1.00
Gujarat Terce Laboratories Ltd 59.8 Cr. 80.694.9/25.822.9 11.90.00 %9.72 %3.44 % 10.0
Gujarat Inject (Kerala) Ltd 28.0 Cr. 19.119.5/8.3536.3 6.640.00 %4.06 %3.33 % 10.0
Godavari Drugs Ltd 85.5 Cr. 114155/87.012.8 55.40.00 %12.7 %15.5 % 10.0
Glenmark Life Sciences Ltd 13,221 Cr. 1,0801,335/62031.2 2072.08 %28.1 %21.1 % 2.00
Industry Average19,460.76 Cr1,177.0554.20184.880.33%16.40%16.92%6.61

All Competitor Stocks of J B Chemicals & Pharmaceuticals Ltd

Quarterly Result

MonthSep 2020Dec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023
Sales444548528606593601625785809793762896882
Expenses333377405442466473500612625618599664638
Operating Profit110171124164127128125173185175164232244
OPM %25%31%23%27%21%21%20%22%23%22%21%26%28%
Other Income85625132052113568
Interest2111112688141210
Depreciation17171718161722262828323132
Profit before tax99208132158129114103142150141122194209
Tax %26%26%24%25%24%26%18%26%26%25%28%27%28%
Net Profit7415410111998848510511110688142151
EPS in Rs4.779.976.517.696.325.435.496.797.186.865.669.199.72

Last Updated: Unknown

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: Unknown

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023TTM
Sales8028661,0221,1441,2101,3441,4081,6431,7752,0432,4243,1493,385
Expenses7017608749641,0041,1121,1911,3371,3971,4821,8812,4542,522
Operating Profit101106148180206232218306378560543696862
OPM %13%12%14%16%17%17%15%19%21%27%22%22%25%
Other Income78927-27115850374141112391025
Interest24467115353753649
Depreciation2225283941475756666973114129
Profit before tax84310487146212230194287349597505555709
Tax %20%23%30%31%23%20%28%32%22%25%24%26%
Net Profit6787962100163184139194272449386410514
EPS in Rs40.024.693.635.929.5810.858.2812.0517.6028.9824.9326.4833.18
Dividend Payout %51%32%41%118%26%5%12%21%31%28%33%34%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2012-20132013-20142014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-2023
YoY Net Profit Growth (%)-88.35%-21.52%61.29%63.00%12.88%-24.46%39.57%40.21%65.07%-14.03%6.22%
Change in YoY Net Profit Growth (%)0.00%66.83%82.81%1.71%-50.12%-37.34%64.02%0.64%24.87%-79.10%20.25%

J B Chemicals & Pharmaceuticals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2012-2013 to 2022-2023.

Growth

Compounded Sales Growth
10 Years:13%
5 Years:16%
3 Years:19%
TTM:11%
Compounded Profit Growth
10 Years:20%
5 Years:24%
3 Years:10%
TTM:26%
Stock Price CAGR
10 Years:33%
5 Years:54%
3 Years:29%
1 Year:13%
Return on Equity
10 Years:16%
5 Years:20%
3 Years:19%
Last Year:20%

Last Updated: Unknown

Balance Sheet

Last Updated: November 14, 2024, 10:31 pm

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Sep 2024
Equity Capital17171717171716151515151616
Reserves1,0031,0269781,1671,3471,4251,4641,4201,7942,1192,4652,9083,197
Borrowings509312719349292629455557237893
Other Liabilities230215365270262294286349376412495687724
Total Liabilities1,3001,3511,4871,6481,6741,7651,7921,8142,2312,6013,5473,9884,029
Fixed Assets3343113294406796406216516341,2771,9012,0042,016
CWIP5465513541715162619557642
Investments39850055247941143445740367813206388345
Other Assets5634945525945806746997438941,2931,3851,5191,627
Total Assets1,3001,3511,4871,6481,6741,7651,7921,8142,2312,6013,5473,9884,029

Reserves and Borrowings Chart

Cash Flow

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Cash from Operating Activity +84-14127140201123194276315170626801
Cash from Investing Activity +-116-142-112-26-45-21-2824-2312-962-404
Cash from Financing Activity +-3112-1-100-184-60-156-306-87-138357-385
Net Cash Flow-63-1441315-284311-6-3342011

Free Cash Flow

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Free Cash Flow101.0056.0055.0053.0013.00183.00189.00280.00349.00515.00488.00124.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Debtor Days818484827278687170846772
Inventory Days104120122146138145149159181178134155
Days Payable6054637168757297979775110
Cash Conversion Cycle124150143158142148146133153164127117
Working Capital Days809956968810197879912710291
ROCE %8%13%13%15%14%11%18%23%33%23%22%25%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthSep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024
Promoters55.91%54.00%54.00%54.00%53.96%53.95%53.93%53.91%53.86%53.83%53.78%53.77%
FIIs8.74%9.12%9.22%8.85%8.66%8.81%8.62%9.53%10.05%10.35%11.06%12.17%
DIIs15.23%16.26%16.89%17.80%18.47%18.55%19.08%18.65%18.58%18.53%18.38%17.61%
Government0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.01%0.00%
Public20.12%20.62%19.89%19.35%18.91%18.72%18.35%17.90%17.50%17.27%16.78%16.42%
No. of Shareholders71,78864,86161,31460,26858,62959,77956,63355,96560,81763,23063,89266,953

Shareholding Pattern Chart

No. of Shareholders

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
Axis Small Cap Fund2,207,4751.79320.28985,9022024-11-20123.9%
Franklin India Smaller Companies Fund1,588,9762.14230.54985,9022024-11-2061.17%
Nippon India Pharma Fund1,486,8683.48215.73985,9022024-11-2050.81%
Nippon India Multi Cap Fund985,9020.63143.04985,9022024-11-200%
Nippon India Small Cap Fund937,8720.33136.08985,9022024-11-20-4.87%
Invesco India Contra Fund804,7040.97116.75985,9022024-11-20-18.38%
Canara Robeco Small Cap Fund790,0681.33114.63985,9022024-11-20-19.86%
HSBC Small Cap Fund - Regular Plan725,1220.82105.21985,9022024-11-20-26.45%
Mirae Asset Healthcare Fund701,3845.16101.76985,9022024-11-20-28.86%
Nippon India Growth Fund684,2920.4699.28985,9022024-11-20-30.59%

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 24Mar 23Mar 22Mar 21Mar 20
FaceValue1.002.002.002.002.00
Basic EPS (Rs.)35.6653.0049.8657.9634.20
Diluted EPS (Rs.)34.8552.3449.8657.9634.20
Cash EPS (Rs.)44.5267.7759.3566.9243.83
Book Value[Excl.RevalReserv]/Share (Rs.)188.36320.55276.73234.65186.07
Book Value[Incl.RevalReserv]/Share (Rs.)188.36320.55276.73234.65186.07
Revenue From Operations / Share (Rs.)224.50407.00313.69264.29229.64
PBDIT / Share (Rs.)60.1991.2075.4087.0655.41
PBIT / Share (Rs.)51.2876.4266.0078.1746.83
PBT / Share (Rs.)48.4271.7665.3377.2345.15
Net Profit / Share (Rs.)35.6152.9949.9558.0435.25
NP After MI And SOA / Share (Rs.)35.6152.9749.8657.9635.20
PBDIT Margin (%)26.8122.4024.0332.9324.13
PBIT Margin (%)22.8418.7721.0329.5720.39
PBT Margin (%)21.5617.6320.8229.2219.65
Net Profit Margin (%)15.8613.0115.9221.9515.34
NP After MI And SOA Margin (%)15.8613.0115.8921.9315.32
Return on Networth / Equity (%)18.9016.5218.0524.7518.95
Return on Capital Employeed (%)25.4519.7122.9331.9124.11
Return On Assets (%)13.8311.5314.7720.0115.00
Long Term Debt / Equity (X)0.010.150.000.000.00
Total Debt / Equity (X)0.120.220.010.010.02
Asset Turnover Ratio (%)0.921.020.910.940.91
Current Ratio (X)2.132.763.324.503.43
Quick Ratio (X)1.561.982.253.492.55
Inventory Turnover Ratio (X)1.751.871.731.961.90
Dividend Payout Ratio (NP) (%)28.4031.1333.0916.3852.02
Dividend Payout Ratio (CP) (%)22.7224.3327.8414.2141.82
Earning Retention Ratio (%)71.6068.8766.9183.6247.98
Cash Earning Retention Ratio (%)77.2875.6772.1685.7958.18
Interest Coverage Ratio (X)21.0719.57113.7992.91141.35
Interest Coverage Ratio (Post Tax) (X)13.4712.3776.3962.9494.21
Enterprise Value (Cr.)25860.2415719.7612145.749693.573932.22
EV / Net Operating Revenue (X)7.424.995.014.752.22
EV / EBITDA (X)27.6822.2820.8414.419.18
MarketCap / Net Operating Revenue (X)7.354.845.024.742.21
Retention Ratios (%)71.5968.8666.9083.6147.97
Price / BV (X)8.766.155.705.352.74
Price / Net Operating Revenue (X)7.354.845.024.742.21
EarningsYield0.020.020.030.040.06

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of J B Chemicals & Pharmaceuticals Ltd as of November 21, 2024 is: 1,805.53

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of November 21, 2024, J B Chemicals & Pharmaceuticals Ltd is Undervalued by 6.08% compared to the current share price 1,702.00

Intrinsic Value of J B Chemicals & Pharmaceuticals Ltd as of November 21, 2024 is: 2,049.64

Calculation basis:

  • Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
  • EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of November 21, 2024, J B Chemicals & Pharmaceuticals Ltd is Undervalued by 20.43% compared to the current share price 1,702.00

Last 5 Year EPS CAGR: 13.52%

*Investments are subject to market risks

Strength and Weakness

StrengthWeakness
  1. The stock has a high average ROCE of 18.17%, which is a positive sign.
  2. The company has higher reserves (1,716.38 cr) compared to borrowings (133.77 cr), indicating strong financial stability.
  3. The company has shown consistent growth in sales (129.62 cr) and profit (370.62 cr) over the years.
  1. The stock has a high average Working Capital Days of 93.58, which may not be favorable.
  2. The stock has a high average Cash Conversion Cycle of 142.08, which may not be favorable.

Stock Analysis

  • Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in J B Chemicals & Pharmaceuticals Ltd:
    1. Net Profit Margin: 15.86%
      • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
    2. ROCE: 25.45% (Industry Average ROCE: 16.25%)
      • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
    3. ROE%: 18.9% (Industry Average ROE: 16.45%)
      • ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
    4. Interest Coverage Ratio (Post Tax): 13.47
      • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
    5. Quick Ratio: 1.56
      • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
    6. Stock P/E: 43.3 (Industry average Stock P/E: 43.76)
      • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
    7. Total Debt / Equity: 0.12
      • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
    The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
    Stock Rating:

About the Company - Qualitative Analysis

J B Chemicals & Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 18/12/1976 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24390MH1976PLC019380 and registration number is 019380. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 2189.88 Cr. and Equity Capital is Rs. 15.46 Cr. for the Year ended 31/03/2022.
INDUSTRYADDRESSCONTACT
PharmaceuticalsNeelam Centre, 'B' Wing, 4th floor, Mumbai Maharashtra 400030secretarial@jbcpl.com
https://jbpharma.com
Management
NamePosition Held
Mr. Arun DuggalChairman & Ind.Director
Mr. Nikhil ChopraWholeTime Director & CEO
Mr. Prashant KumarNon Executive Director
Mr. Gaurav TrehanNon Executive Director
Mr. Akshay TannaNon Executive Director
Mr. Sumit BoseIndependent Director
Ms. Padmini Khare KaickerIndependent Director

FAQ

What is the latest intrinsic value of J B Chemicals & Pharmaceuticals Ltd?

The latest intrinsic value of J B Chemicals & Pharmaceuticals Ltd as on 21 November 2024 is ₹1805.53, which is 6.08% higher than the current market price of ₹1,702.00.

What is the Market Cap of J B Chemicals & Pharmaceuticals Ltd?

The Market Cap of J B Chemicals & Pharmaceuticals Ltd is 26,454 Cr..

What is the current Stock Price of J B Chemicals & Pharmaceuticals Ltd as on 21 November 2024?

The current stock price of J B Chemicals & Pharmaceuticals Ltd as on 21 November 2024 is ₹1,702.

What is the High / Low of J B Chemicals & Pharmaceuticals Ltd stocks in FY 2024?

In FY 2024, the High / Low of J B Chemicals & Pharmaceuticals Ltd stocks is 2,030/1,371.

What is the Stock P/E of J B Chemicals & Pharmaceuticals Ltd?

The Stock P/E of J B Chemicals & Pharmaceuticals Ltd is 43.3.

What is the Book Value of J B Chemicals & Pharmaceuticals Ltd?

The Book Value of J B Chemicals & Pharmaceuticals Ltd is 207.

What is the Dividend Yield of J B Chemicals & Pharmaceuticals Ltd?

The Dividend Yield of J B Chemicals & Pharmaceuticals Ltd is 0.72 %.

What is the ROCE of J B Chemicals & Pharmaceuticals Ltd?

The ROCE of J B Chemicals & Pharmaceuticals Ltd is 24.6 %.

What is the ROE of J B Chemicals & Pharmaceuticals Ltd?

The ROE of J B Chemicals & Pharmaceuticals Ltd is 20.0 %.

What is the Face Value of J B Chemicals & Pharmaceuticals Ltd?

The Face Value of J B Chemicals & Pharmaceuticals Ltd is 1.00.

About the Author

Author Avatar
Getaka

Getaka, CFA, a financial analyst with 15 years of experience in the industry. Getaka holds an MBA degree and the Chartered Financial Analyst designation, demonstrating his profound understanding of financial analysis and investment management. Throughout his career, he has conducted numerous financial analyses and due diligence processes for companies in the industry, and has a strong track record of identifying key trends and opportunities. He leverages his expertise to deliver a thorough financial analysis of a company, encompassing its financial performance, key ratios, future prospects, and risks. Getaka is committed to providing accurate, reliable, and trustworthy information to help readers make informed decisions about their finances and investments.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in J B Chemicals & Pharmaceuticals Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE